If you have ulcerative colitis and your gastroenterologist has prescribed Entyvio, the honest answer to "does Blue Cross Blue Shield cover Entyvio for ulcerative colitis" is that it depends on which Blue plan you have. Blue Cross Blue Shield is not a single insurer. It is a federation of more than 30 independent, locally operated companies, each writing its own medical and pharmacy coverage policies. A criterion that applies to a member in Massachusetts may not match the rules for a member in Texas or a federal employee. Most Blue plans do cover Entyvio for moderately to severely active ulcerative colitis, but coverage almost always comes with prior authorization and documentation requirements. This article explains how to find your own plan's answer and what approval typically requires.
Why Coverage Varies Across Blue Plans
There is no national Blue Cross Blue Shield formulary. Each independent licensee sets its own drug list, tier placement, prior-authorization criteria, and step-therapy rules, and those rules are administered through different pharmacy benefit managers. Many Blue plans contract with Prime Therapeutics, which describes itself as serving several Blue Cross and Blue Shield plans across states including Illinois, Texas, Minnesota, and Florida. Other Blue plans, including several operated by Anthem, route pharmacy benefits through CarelonRx. Because the PBM and the local plan together decide which drugs are preferred and what must be tried first, two people who both carry a Blue Cross card can face different Entyvio rules. The practical takeaway is to treat your specific plan's published policy as the only authoritative source.
What Entyvio Is and Why Plans Cover It for UC
Entyvio, the brand name for vedolizumab, is an integrin receptor antagonist indicated in adults for moderately to severely active ulcerative colitis. It works differently from older biologics. As the Federal Employee Program Entyvio policy describes, vedolizumab binds the alpha-4-beta-7 integrin and blocks its interaction with MAdCAM-1, which is mainly expressed on gut endothelial cells, so its effect is largely gut-selective. The drug is given as an intravenous infusion at weeks 0, 2, and 6, after which a patient may stay on IV every eight weeks or switch to a 108 mg subcutaneous injection once every two weeks. This gut-selective profile is part of why guidelines and Blue plans treat it as a strong UC option rather than a last resort.
The Prior Authorization and Step-Therapy Hurdle
Across Blue plans, Entyvio for ulcerative colitis is consistently gated by prior authorization. The Blue Cross Blue Shield of Massachusetts pharmacy policy flags prior authorization for Entyvio and notes it can be adjudicated under either the pharmacy or the medical benefit. The most common criterion is documented failure of conventional therapy. The Federal Employee Program policy, for example, requires an inadequate response, intolerance, or contraindication to at least one conventional therapy option before Entyvio is considered medically necessary. Conventional therapy generally means agents such as corticosteroids and immunomodulators like azathioprine. Some plans add a re-evaluation requirement, confirming therapeutic benefit at week 14 before continued coverage is authorized.
How to Find Your Own Plan's Entyvio Rules
Because the rules are plan-specific, the fastest path to a real answer is to read your own plan's documents. Start with the member portal or the back of your insurance card to identify the exact Blue licensee and pharmacy benefit manager, then locate two things.
Your plan's formulary or drug list, to see Entyvio's tier and whether it sits on the pharmacy or medical benefit
Your plan's medical or pharmacy policy for vedolizumab, which spells out the prior-authorization criteria
Search your plan's provider site for "vedolizumab" or "Entyvio medical policy." These documents are public and list the precise step-therapy and documentation requirements your prescriber must satisfy. If the benefit split is unclear, call the member services number, since an infused drug like Entyvio may be billed under the medical benefit rather than pharmacy, which changes how prior authorization is submitted.
Building a Strong Medical-Necessity Case
Whatever your specific Blue plan requires, the evidence that wins approval is similar. The criteria reward a documented treatment history and a clear clinical picture. Society guidance supports Entyvio as an appropriate choice for many patients: the AGA living guideline on moderate-to-severe ulcerative colitis recommends vedolizumab over no treatment and positions it as a higher-efficacy option, suggesting infliximab or vedolizumab over adalimumab for biologic-naive patients. A complete prior-authorization request usually includes the diagnosis with disease severity, the conventional therapies already tried with dates and outcomes, and any contraindications. Chart notes documenting active symptoms such as rectal bleeding and stool frequency strengthen the case. If your plan denies the request, you have the right to appeal, and a well-documented record of prior treatment failures is typically the deciding factor on review.
The Bottom Line for Blue Cross Members
Blue Cross Blue Shield plans generally do cover Entyvio for moderately to severely active ulcerative colitis, and the drug's gut-selective mechanism and guideline support make it a frequently approved option. The variable that matters is your specific plan. Coverage, formulary tier, the pharmacy-versus-medical benefit split, the pharmacy benefit manager, and the exact step-therapy requirements all depend on which independent Blue licensee issued your policy. Rather than relying on a national generic answer or a manufacturer page that cannot see your plan, read your own plan's published vedolizumab policy and formulary, confirm which conventional therapies you must document, and prepare a thorough medical-necessity record. That preparation, more than any single coverage rule, is what carries a request through prior authorization and, if needed, through an appeal.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.